Amorphex Therapeutics

Executive Summary

Amorphex Therapeutics is a privately held, preclinical-stage biotechnology company headquartered in Cambridge, Massachusetts, focused on revolutionizing ocular drug delivery through its proprietary TODDD™ platform. Founded in 2018, the company has developed a patented, non-invasive ocular insert designed to provide continuous, sustained drug release to the eye over periods ranging from weeks to over 90 days. This technology aims to address significant limitations of traditional eye drops, such as poor patient adherence, inconsistent dosing, and low bioavailability, which often undermine treatment outcomes for chronic ophthalmic conditions like glaucoma, dry eye disease, and post-surgical inflammation. By enabling a single administration to deliver therapeutics for extended durations, TODDD™ has the potential to improve efficacy, convenience, and quality of life for millions of patients worldwide. As a preclinical entity, Amorphex is currently advancing its platform through necessary animal studies and formulation optimization to demonstrate proof-of-concept and safety. The company's primary near-term focus is to complete in vivo validation studies and engage with potential strategic partners or investors to support an Investigational New Drug (IND) application. While still early-stage, the unmet need for improved ocular drug delivery and the robustness of the TODDD™ platform position Amorphex as an attractive opportunity in the ophthalmic space. Key upcoming milestones include completion of pivotal preclinical studies, potential Series A financing, and initiation of IND-enabling toxicology studies.

Upcoming Catalysts (preview)

• Q4 2026Completion of pivotal preclinical efficacy studies in animal models70% success
• Q1 2027Series A financing round75% success
• Q3 2027IND filing for lead indication40% success